<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005226.pub2" GROUP_ID="NEUROMUSC" ID="391304020311474339" MERGED_FROM="" MODIFIED="2013-05-22 09:56:52 +0100" MODIFIED_BY="Ruth Brassington" REVIEW_NO="050" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.4">
<COVER_SHEET MODIFIED="2013-05-22 09:56:52 +0100" MODIFIED_BY="Ruth Brassington">
<TITLE>Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease</TITLE>
<CONTACT MODIFIED="2013-05-22 09:56:52 +0100" MODIFIED_BY="Ruth Brassington"><PERSON ID="CB583EBA82E26AA2014E8D67E01D73D1" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Johannes</FIRST_NAME><LAST_NAME>Brettschneider</LAST_NAME><EMAIL_1>johannes.brettschneider@uni-ulm.de</EMAIL_1><ADDRESS><DEPARTMENT>Neurology</DEPARTMENT><ORGANISATION>University of Ulm</ORGANISATION><ADDRESS_1>Oberer Eselsberg 45</ADDRESS_1><CITY>Ulm</CITY><ZIP>89081</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+ 0731 177 1201</PHONE_1><FAX_1>+ 0731 177 1519</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-05-22 09:56:52 +0100" MODIFIED_BY="Ruth Brassington"><PERSON ID="CB583EBA82E26AA2014E8D67E01D73D1" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Johannes</FIRST_NAME><LAST_NAME>Brettschneider</LAST_NAME><EMAIL_1>johannes.brettschneider@uni-ulm.de</EMAIL_1><ADDRESS><DEPARTMENT>Neurology</DEPARTMENT><ORGANISATION>University of Ulm</ORGANISATION><ADDRESS_1>Oberer Eselsberg 45</ADDRESS_1><CITY>Ulm</CITY><ZIP>89081</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+ 0731 177 1201</PHONE_1><FAX_1>+ 0731 177 1519</FAX_1></ADDRESS></PERSON><PERSON ID="F7AB9F1A82E26AA201E74FE90A18F65A" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jerome</FIRST_NAME><LAST_NAME>Kurent</LAST_NAME><POSITION>Professor of Medicine, Neurology and Psychiatry</POSITION><EMAIL_1>kurentje@musc.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurosciences</DEPARTMENT><ORGANISATION>Medical University of South Carolina</ORGANISATION><ADDRESS_1>96 Jonathan Lucas Street, Suite 307</ADDRESS_1><CITY>Charleston, South Carolina</CITY><ZIP>29425</ZIP><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 843 792 3590</PHONE_1><FAX_1>+1 843 792 8626</FAX_1></ADDRESS></PERSON><PERSON ID="CB62AD1382E26AA2014E8D6748BBEE98" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Albert</FIRST_NAME><LAST_NAME>Ludolph</LAST_NAME><POSITION>Director and Chair</POSITION><EMAIL_1>albert.ludolph@rku.de</EMAIL_1><ADDRESS><DEPARTMENT>Neurology</DEPARTMENT><ORGANISATION>University of Ulm</ORGANISATION><ADDRESS_1>Oberer Eselsberg 45</ADDRESS_1><CITY>Ulm</CITY><ZIP>89081</ZIP><REGION>Baden Württemberg</REGION><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 731 177 1200</PHONE_1><FAX_1>+49 731 177 1202</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-04-11 14:49:07 +0100" MODIFIED_BY="Kate Jewitt">
<UP_TO_DATE>
<DATE DAY="3" MONTH="7" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="7" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="3" MONTH="7" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2013-04-11 14:51:14 +0100" MODIFIED_BY="Kate Jewitt">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-04-11 14:50:56 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="11" MONTH="4" YEAR="2013"/>
<DESCRIPTION>
<P>Searches updated to 3 July 2012. No RCTs identified for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-04-11 14:51:14 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="11" MONTH="4" YEAR="2013"/>
<DESCRIPTION>
<P>Minor revisions to text. Search for ongoing studies completed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-04-11 14:49:17 +0100" MODIFIED_BY="Kate Jewitt">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-04-11 14:49:17 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="2" MONTH="8" YEAR="2010"/>
<DESCRIPTION>
<P>Searches updated to May 2010. No randomised controlled trials identified. Some additional non-randomised studies referenced in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-04-29 09:53:42 +0100" MODIFIED_BY="Kate Jewitt">
<DATE DAY="13" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-10-04 14:14:37 +0100" MODIFIED_BY="Kate Jewitt">
<INTERNAL_SOURCES MODIFIED="2010-10-04 14:14:04 +0100" MODIFIED_BY="Kate Jewitt">
<SOURCE MODIFIED="2010-10-04 14:14:04 +0100" MODIFIED_BY="Kate Jewitt">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-10-04 14:14:37 +0100" MODIFIED_BY="Kate Jewitt">
<SOURCE MODIFIED="2010-10-04 14:14:37 +0100" MODIFIED_BY="Kate Jewitt">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-05-10 14:59:10 +0100" MODIFIED_BY="Kate Jewitt">
<SUMMARY MODIFIED="2013-04-30 09:47:00 +0100" MODIFIED_BY="Kate Jewitt">
<TITLE>Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease</TITLE>
<SUMMARY_BODY MODIFIED="2013-04-30 09:47:00 +0100" MODIFIED_BY="Kate Jewitt">
<P>Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is the most common neurodegenerative disorder of the motor system in adults. Pain is a frequent symptom and may have a pronounced impact on quality of life and suffering. Despite an extensive search of different medical databases, this review was not able to identify any randomised controlled trials on drug therapy for pain in ALS. Currently (to July 2012) no evidence exists for using one type of treatment over another.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-04-30 09:46:00 +0100" MODIFIED_BY="Kate Jewitt">
<ABS_BACKGROUND MODIFIED="2013-04-30 09:45:58 +0100" MODIFIED_BY="Kate Jewitt">
<P>Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is the most common neurodegenerative disorder of the motor system in adults. Pain in ALS is a frequent symptom especially in the later stages of disease and can have a pronounced influence on quality of life and suffering. Treatment of pain therefore should be recognised as an important aspect of palliative care in ALS. This is an update of a review first published in 2008.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To systematically review the evidence for the efficacy of drug therapy in relieving pain in ALS. We also aimed to evaluate possible adverse effects associated with the different drugs and their influence on survival and quality of life. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-04-30 09:46:00 +0100" MODIFIED_BY="Kate Jewitt">
<P>On 2 July 2012, we searched the following databases: the Cochrane Neuromuscular Disease Group Specialized Register (2 July 2012), CENTRAL (2012, Issue 6 in <I>The Cochrane Library</I>), MEDLINE (January 1966 to June 2012), EMBASE (January 1980 to June 2012), CINAHL (January 1982 to June 2012), AMED (January 1985 to June 2012) and LILACS (January 1982 to June 2012). We checked the bibliographies of trials identified and contacted other disease experts to identify further published and unpublished trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We searched for randomised or quasi-randomised controlled trials on drug therapy for pain in amyotrophic lateral sclerosis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-09-08 10:07:14 +0100" MODIFIED_BY="Kate Jewitt">
<P>We collected data using a specially designed form and analysed them using the Cochrane Review Manager software.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-09-08 10:07:32 +0100" MODIFIED_BY="Kate Jewitt">
<P>We found no randomised or quasi-randomised controlled trials on drug therapy for pain in ALS or MND.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-04-30 10:20:10 +0100" MODIFIED_BY="Kate Jewitt">
<P>There is no evidence from randomised controlled trials about the management of pain in ALS. Further research on this important aspect of palliative care in ALS is needed. Randomised controlled trials should be initiated to determine the effectiveness of different analgesics for treatment of pain in ALS.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-04-30 09:51:48 +0100" MODIFIED_BY="Kate Jewitt">
<BACKGROUND MODIFIED="2013-04-30 09:47:06 +0100" MODIFIED_BY="Kate Jewitt">
<P>Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is the most common neurodegenerative disorder of the motor system in adults. The incidence is up to 2 per 100,000 population per year and age specific incidence and mortality rates peak between 55 and 75 years (<LINK REF="REF-Worms-2001" TYPE="REFERENCE">Worms 2001</LINK>). People with ALS show a combination of upper and lower motor neuron signs and death usually results from respiratory failure. Over 50% of people with ALS die within three years of the first symptom.</P>
<P>Although less of an issue in the earlier stages of the disease, pain has been reported to be a frequent symptom in the later stages of ALS (<LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>), where studies have reported pain to occur in up to 80% of cases (<LINK REF="REF-Gubbay-1985" TYPE="REFERENCE">Gubbay 1985</LINK>; <LINK REF="REF-Miller-1999" TYPE="REFERENCE">Miller 1999</LINK>; <LINK REF="STD-Newrick-1985" TYPE="STUDY">Newrick 1985</LINK>; <LINK REF="STD-Saunders-1981" TYPE="STUDY">Saunders 1981</LINK>; <LINK REF="STD-Wu-1998" TYPE="STUDY">Wu 1998</LINK>). Pain mainly affects the lower back, shoulders, neck and legs (<LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>; <LINK REF="STD-Wu-1998" TYPE="STUDY">Wu 1998</LINK>) and may have a dull or electrical character (<LINK REF="STD-Newrick-1984" TYPE="STUDY">Newrick 1984</LINK>; <LINK REF="STD-Newrick-1985" TYPE="STUDY">Newrick 1985</LINK>). Patients sometimes report pain of a different quality in different parts of the body. Although in most cases the severity of the pain is reported to be mild or moderate, severe pain is reported in 20% of patients (<LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>; <LINK REF="STD-Newrick-1985" TYPE="STUDY">Newrick 1985</LINK>). It has been suggested that the intensity of pain increases with disease duration (<LINK REF="REF-Drory-2001" TYPE="REFERENCE">Drory 2001</LINK>).</P>
<P>The aetiology of pain in patients with ALS is not well understood. Musculoskeletal pain may arise in the later stages of disease as a result of stress on bones and joints that have lost their protective muscular sheath due to atrophy (Borasio 1997; <LINK REF="STD-Borasio-2001a" TYPE="STUDY">Borasio 2001a</LINK>). In addition, pain may be caused by muscle contractures and joint stiffness (Borasio 1997; <LINK REF="STD-Borasio-2001a" TYPE="STUDY">Borasio 2001a</LINK>). This may explain why pain seems to be a particular feature in the later stages of the disease. Pain may also arise from muscle cramps and muscle spasticity. Another cause of pain in patients with ALS seems to be skin pressure caused by immobility (Borasio 1997). In this context, decubitus ulcers have been reported in 16% of patients (<LINK REF="STD-Saunders-1981" TYPE="STUDY">Saunders 1981</LINK>). Pain may also occur as a manifestation of the sensory disturbances which are reported to occur in up to 11% of patients (<LINK REF="REF-Lawyer-1953" TYPE="REFERENCE">Lawyer 1953</LINK>). Pathological involvement of sensory pathways in motor neuron disease has only infrequently been reported (<LINK REF="REF-Brownell-1970" TYPE="REFERENCE">Brownell 1970</LINK>). A potentially associated chronic central pain syndrome was reported in a single patient (<LINK REF="STD-Drake-1983" TYPE="STUDY">Drake 1983</LINK>).</P>
<P>The first line treatment for pain in ALS is usually non-opioid analgesics, including acetaminophen, or non-steroidal anti-inflammatory agents (NSAIDs) (<LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>; <LINK REF="STD-Wu-1998" TYPE="STUDY">Wu 1998</LINK>). Opioid drugs are usually used if these drugs fail to relieve the pain (<LINK REF="STD-O_x0027_Brien-1992" TYPE="STUDY">O'Brien 1992</LINK>). Opioids may also be used for the symptomatic treatment of dyspnoea and coughing in MND (<LINK REF="STD-Neudert-2001" TYPE="STUDY">Neudert 2001</LINK>; <LINK REF="STD-Oliver-1998" TYPE="STUDY">Oliver 1998</LINK>). There is considerable discrepancy in the literature regarding the frequency of dosing and actual dose provided, as well as the routes of administration of opioids in ALS (<LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>; <LINK REF="STD-Neudert-2001" TYPE="STUDY">Neudert 2001</LINK>; <LINK REF="STD-Wu-1998" TYPE="STUDY">Wu 1998</LINK>). Opioids are possibly more frequently used in patients treated in hospices or palliative care units (<LINK REF="STD-Neudert-2001" TYPE="STUDY">Neudert 2001</LINK>). It is possible that some health professionals might be hesitant to use opioids for fear that they might hasten death by suppressing ventilation (<LINK REF="STD-Oliver-1998" TYPE="STUDY">Oliver 1998</LINK>) and because patients and family caregivers might associate opiate drugs with terminal stages of disease and imminent death (<LINK REF="STD-Oliver-1998" TYPE="STUDY">Oliver 1998</LINK>).</P>
<P>Continuing uncertainty over the indications, doses, application modes and side effects of pain medication in the palliative therapy of patients with ALS suggests that a systematic review of all randomised clinical trials concerning treatment of pain in ALS is required. The results will need to be considered in the context of non-randomised studies in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> section of this review.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The objective of this review was to systematically review the evidence for the efficacy of drug therapy in relieving pain in ALS. We also aimed to evaluate possible adverse effects associated with the different drugs and their influence on survival and quality of life. </P>
</OBJECTIVES>
<METHODS MODIFIED="2013-04-30 09:50:27 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-04-30 09:47:26 +0100" MODIFIED_BY="Ruth Brassington">
<CRIT_STUDIES MODIFIED="2013-04-30 09:47:18 +0100" MODIFIED_BY="Ruth Brassington">
<P>All randomised and quasi-randomised (alternate or other systematic allocation) controlled studies involving drug therapy administered to relieve pain in ALS or MND. We did not include studies of treatments for cramps in ALS or MND as this is the topic of another Cochrane review (<LINK REF="REF-Baldinger-2012" TYPE="REFERENCE">Baldinger 2012</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-04-30 10:20:10 +0100" MODIFIED_BY="Kate Jewitt">
<P>All those with a clinical diagnosis of ALS or MND (pure mixed upper motor neuron and lower motor neuron degeneration with a supportive electromyogram) according to the revised El Escorial criteria (<LINK REF="REF-Brooks-2000" TYPE="REFERENCE">Brooks 2000</LINK>)) and with any clinical pattern of the condition (e.g. bulbar or limb onset) who report experiencing pain.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any drug therapy, given by any route, in any dose, administered to relieve pain in ALS/MND. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-04-30 09:47:26 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-04-14 14:44:42 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome was patient reported pain relief after 24 hours (site, intensity, frequency and duration of pain) measured by a visual analogue scale, verbal or numerical rating scale, or any other validated assessment tool.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-04-30 09:47:26 +0100" MODIFIED_BY="Kate Jewitt">
<P>The secondary outcome measures were:<BR/>(1) patient reported pain relief after seven days;<BR/>(2) adverse effects of treatment. An assessment of the severity and frequency of the reported adverse effects was made. Adverse effects were categorised into those severe enough to result in cessation of treatment (for example respiratory depression as an adverse effect of opioids) and those that were mild.</P>
<P>Wherever possible, we planned to transform visual analogue scales and any categorical outcomes and analyse them as dichotomous data.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-04-30 09:47:49 +0100" MODIFIED_BY="[Empty name]">
<P>(1) We searched the Cochrane Neuromuscular Disease Group Specialized Register (2 July 2012), CENTRAL (2012, Issue 6 in <I>The Cochrane Library)</I>, MEDLINE (January 1966 to June 2012), EMBASE (January 1980 to June 2012), CINAHL (January 1982 to June 2012), AMED (January 1985 to June 2012) and LILACS (January 1982 to June 2012).</P>
<P>(2) In addition, we reviewed the results of the RCT searches of MEDLINE (January 1966 to June 2012) and EMBASE (January 1980 to June 2012) for well-designed published observational studies of pain therapy in terminal ALS, with controls, where the diagnosis was clearly stated, the interventions were clearly described and the outcomes were clearly reported for all patients. For example, we collected prospective cohort studies or case control studies with concurrent controls. We also considered retrospective case series of more than five participants where patients were treated consecutively. This strategy was deemed necessary because we suspected there would be few or no randomised controlled trials or quasi-randomised controlled trials on this particular topic, as we believed it would be unethical to design a placebo controlled trial for treatment of pain in ALS.</P>
<P>For this update, on 9 April 2013, we also searched the US national Institutes of Health registry ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov">http://clinicaltrials.gov</A>) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>) for ongoing trials.</P>
<SUBSECTION>
<HEADING LEVEL="3">Electronic searches</HEADING>
<P>The detailed search strategies are in the appendices:MEDLINE (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), EMBASE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), CINAHL Plus (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), AMED (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), LILACS (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>), CENTRAL <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>, ClinicalTrials.gov and WHO ICTRP (<LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Searching other resources</HEADING>
<P>We planned to check the bibliographies of trials identified and contacted other disease experts for further published and unpublished trials.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-04-30 09:50:27 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (previously JB, JD Mitchell (JDM); for this update, JB and JK) checked all titles and abstracts identified by the searches for randomised or quasi-randomised trials. Two authors (previously JB, JDM; for this update, JB and JK) also checked all titles and abstracts identified by the searches for non-randomised evidence. The authors obtained the full texts of all potentially relevant studies and assessed them independently. Two authors extracted data independently onto a specially designed form (JB, JDM; not required for this update). One author (JB) entered the data into the software and two checked the data entered (JK, AL). All the authors decided which trials met the inclusion criteria for the review. Disagreement about inclusion was resolved by discussion and consensus between the authors.</P>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias in included studies</HEADING>
<P>Had there been RCTs two authors would have independently assessed risk of bias using in the following domains using the criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>):</P>
<UL>
<LI>secure randomisation;</LI>
<LI>allocation concealment;</LI>
<LI>blinding of subject and observer;</LI>
<LI>blinding of outcome assessors;</LI>
<LI>completeness of follow up and intention-to-treat analysis;</LI>
<LI>selective outcome reporting;</LI>
<LI>other sources of bias.</LI>
</UL>
<P>We would have quantified the risk of bias as follows: Low risk of bias, High risk of bias, or Unclear risk of bias (insufficient detail reported, risk of bias unknown or the entry is not relevant to the study). Where there was an unclear risk of bias , we would have tried to obtain further information from the trial investigators.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data collection</HEADING>
<P>We designed a data collection form for the review and planned to collect the following data:<BR/>
</P>
<UL>
<LI>publication details;</LI>
<LI>participants: number of patients, gender, mean age, disease duration, clinical subtype of ALS (bulbar, limb, both bulbar and limb);</LI>
<LI>trial quality characteristics;</LI>
<LI>site of pain;</LI>
<LI>cause of pain;</LI>
<LI>duration of pain;</LI>
<LI>description of intervention;</LI>
<LI>outcome data;</LI>
<LI>adverse effects.</LI>
</UL>
<P>We planned to obtain missing or additional data from the authors wherever possible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>The Cochrane Neuromuscular Disease Group guidelines were followed. We planned to analyse the data using Cochrane Review Manager software (currently <LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>) and to report it according to the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(currently <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>)<I>.</I>.</P>
<P>We aimed to calculate the risk ratio (RR) and corresponding 95% confidence intervals (CI) for dichotomous data and the mean difference (MD) and 95% confidence intervals (CI) for continuous data.<BR/>Analyses of subgroups identifying different drug treatments and different doses were to be carried out if sufficient data had been available. Wherever possible, we intended to compare different subgroups of pain medication.<BR/>
<BR/>We planned to test for heterogeneity across trials and if heterogeneity could be found we intended to undertake sensitivity analyses by repeating the calculation omitting trials that had low scores on individual quality items. If heterogeneity could not be explained by variation in trial quality we intended to use a random-effects approach to obtain the pooled estimates from the group of trials.</P>
<P>This review has a published protocol (<LINK REF="REF-Brettschneider-2005" TYPE="REFERENCE">Brettschneider 2005</LINK>). If at a future update new trials emerge we will update the methodology according to Cochrane Collaboration guidance at that time.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-04-30 09:51:10 +0100" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;The number of papers found by the new, current strategies are&lt;/p&gt;&lt;p&gt;MEDLINE - 151 (10 new papers)&lt;/p&gt;&lt;p&gt;EMBASE - 229 (76 new papers)&lt;/p&gt;&lt;p&gt;Cochrane Neuromuscular Disease Group Specialized Register &amp;#160;- 15 (1new paper)&lt;/p&gt;&lt;p&gt;CENTRAL - 13&lt;/p&gt;&lt;p&gt;AMED - 8 (1new paper)&lt;/p&gt;&lt;p&gt;CINAHL Plus - 27 (6new papers)&lt;/p&gt;&lt;p&gt;LILACS - 0&lt;/p&gt;&lt;p&gt;The NMD Group is now following the Cochrane policy of giving the total number of references found by each database, the number of references after deduplication, the number of references selected for further review and the number meeting the inclusion criteria for the review.&lt;/p&gt;" NOTES_MODIFIED="2013-04-30 09:51:10 +0100" NOTES_MODIFIED_BY="Kate Jewitt">
<STUDY_DESCRIPTION MODIFIED="2013-04-30 09:51:10 +0100" MODIFIED_BY="Kate Jewitt">
<P>The number of references retrieved by the new, current electronic searches for the review were: MEDLINE 151 (10 new papers), EMBASE = 229 (76 new papers), AMED = 8 (1 new paper), LILACS = 0, CINAHL Plus = 27 (6 new papers), CENTRAL = 13 and the Cochrane NMD Group Specialised Register 15 (1 new paper). After screening, no randomised or quasi-randomised controlled trials on drug therapy for pain in ALS or MND were found. There was one randomised controlled study on gabapentin (which is often used for treatment of pain) in ALS, but pain was not an outcome measure in that study (<LINK REF="REF-Miller-2001" TYPE="REFERENCE">Miller 2001</LINK>). We could find no well designed published observational studies on pain therapy in ALS. We found one Cochrane review on treatment for spasticity in ALS/MND, although it identified no randomised trials examining the effectiveness of anti-spasticity drugs (<LINK REF="REF-Ashworth-2006" TYPE="REFERENCE">Ashworth 2006</LINK>).</P>
<P>In total there are 34 excluded studies. At this update we excluded <LINK REF="STD-Weber-2010" TYPE="STUDY">Weber 2010</LINK>, which is included in the Cochrane review of treatments for cramp in ALS (<LINK REF="REF-Baldinger-2012" TYPE="REFERENCE">Baldinger 2012</LINK>). We removed three reviews from the excluded studies tables (<LINK REF="REF-Ashworth-2006" TYPE="REFERENCE">Ashworth 2006</LINK>; <LINK REF="REF-Borasio-1997" TYPE="REFERENCE">Borasio 1997</LINK>; <LINK REF="REF-Borasio-2001b" TYPE="REFERENCE">Borasio 2001b</LINK>).</P>
<P>We found 13 case series of more than five participants describing drug therapy for pain in ALS (<LINK REF="STD-Amtmann-2004" TYPE="STUDY">Amtmann 2004</LINK>; <LINK REF="STD-Bedlack-2009" TYPE="STUDY">Bedlack 2009</LINK>; <LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>; <LINK REF="STD-Ganzini-2002b" TYPE="STUDY">Ganzini 2002b</LINK>; <LINK REF="STD-McClelland-2008" TYPE="STUDY">McClelland 2008</LINK>; <LINK REF="STD-Neudert-2001" TYPE="STUDY">Neudert 2001</LINK>; <LINK REF="STD-Newrick-1984" TYPE="STUDY">Newrick 1984</LINK>; <LINK REF="STD-Newrick-1985" TYPE="STUDY">Newrick 1985</LINK>; <LINK REF="STD-O_x0027_Brien-1992" TYPE="STUDY">O'Brien 1992</LINK>; <LINK REF="STD-Oliver-1996" TYPE="STUDY">Oliver 1996</LINK>; <LINK REF="STD-Oliver-1998" TYPE="STUDY">Oliver 1998</LINK>; <LINK REF="STD-Saunders-1981" TYPE="STUDY">Saunders 1981</LINK>; <LINK REF="STD-Wu-1998" TYPE="STUDY">Wu 1998</LINK>).<BR/>
<BR/>Further data included case series (<LINK REF="STD-Adelman-2004" TYPE="STUDY">Adelman 2004</LINK>; <LINK REF="STD-Abe-2008" TYPE="STUDY">Abe 2008</LINK>; <LINK REF="STD-Bradley-2001" TYPE="STUDY">Bradley 2001</LINK>; <LINK REF="STD-de-Castro_x002d_Costa-1999" TYPE="STUDY">de Castro-Costa 1999</LINK>; <LINK REF="STD-Ganzini-1998" TYPE="STUDY">Ganzini 1998</LINK>; <LINK REF="STD-Hecht-2002" TYPE="STUDY">Hecht 2002</LINK>; <LINK REF="STD-Jensen-2005" TYPE="STUDY">Jensen 2005</LINK>; <LINK REF="STD-Tedman-1997" TYPE="STUDY">Tedman 1997</LINK>; <LINK REF="STD-Trail-2003" TYPE="STUDY">Trail 2003</LINK>; <LINK REF="STD-Winter-2010" TYPE="STUDY">Winter 2010</LINK>) and case reports (<LINK REF="STD-de-Carvalho-2001" TYPE="STUDY">de Carvalho 2001</LINK>; <LINK REF="STD-Drake-1983" TYPE="STUDY">Drake 1983</LINK>; <LINK REF="STD-Shibata-2003" TYPE="STUDY">Shibata 2003</LINK>) as well as surveys of expert opinion (<LINK REF="STD-Abe-2008" TYPE="STUDY">Abe 2008</LINK>; <LINK REF="STD-Borasio-2001a" TYPE="STUDY">Borasio 2001a</LINK>; <LINK REF="STD-Carter-2010" TYPE="STUDY">Carter 2010</LINK>; <LINK REF="STD-Chio-2001" TYPE="STUDY">Chio 2001</LINK>; <LINK REF="STD-Forshew-2003" TYPE="STUDY">Forshew 2003</LINK>) or caregivers' experience (<LINK REF="STD-Ganzini-2002a" TYPE="STUDY">Ganzini 2002a</LINK>; <LINK REF="STD-Maessen-2010" TYPE="STUDY">Maessen 2010</LINK>; <LINK REF="STD-Mandler-2001" TYPE="STUDY">Mandler 2001</LINK>) describing certain aspects such as causes, frequency, localisation or intensity of pain in ALS.</P>
<P>We found no relevant ongoing studies.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>No evidence above the level of case series was found.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-10-04 14:18:17 +0100" MODIFIED_BY="Kate Jewitt">
<P>We did not find any randomised or quasi-randomised controlled trials on drug therapy for pain in ALS or MND in the Cochrane Neuromuscular Disease Group Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, LILACS or AMED, or any other sources.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-04-30 09:51:48 +0100" MODIFIED_BY="Kate Jewitt">
<SUBSECTION>
<HEADING LEVEL="2">Frequency of pain</HEADING>
<P>Evidence derived from case series, surveys of expert opinion and case reports showed pain in ALS to occur in between 3% and 78% of patients (<LINK REF="STD-Bradley-2001" TYPE="STUDY">Bradley 2001</LINK>; <LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>; Maessen 2010; Winter 2010; <LINK REF="STD-Wu-1998" TYPE="STUDY">Wu 1998</LINK>). Frequency of pain has been shown to increase with ongoing disease (<LINK REF="STD-Hecht-2002" TYPE="STUDY">Hecht 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Intensity and relevance of pain</HEADING>
<P>Intensity of pain was shown to be mostly moderate in the earlier stages of ALS, though it was demonstrated to increase with ongoing disease (<LINK REF="STD-Adelman-2004" TYPE="STUDY">Adelman 2004</LINK>; <LINK REF="STD-Ganzini-2002b" TYPE="STUDY">Ganzini 2002b</LINK>). In a case series including 126 patients with MND, mean severity of pain was rated with 25.6 points on a 100 point visual analogue scale (20.8 to 30.4, 95% CI) (<LINK REF="REF-Clarke-2005" TYPE="REFERENCE">Clarke 2005</LINK>). In the final stages of disease, pain was noted to be of severe intensity in up to 20% of patients (<LINK REF="STD-Ganzini-1998" TYPE="STUDY">Ganzini 1998</LINK>; <LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>; <LINK REF="STD-Ganzini-2002a" TYPE="STUDY">Ganzini 2002a</LINK>; <LINK REF="STD-Ganzini-2002b" TYPE="STUDY">Ganzini 2002b</LINK>). Agreement between patients and caregivers for ratings of pain level was shown to be high (<LINK REF="STD-Adelman-2004" TYPE="STUDY">Adelman 2004</LINK>).<BR/>
<BR/>Pain in ALS was shown to correlate significantly with depression ratings (<LINK REF="STD-Tedman-1997" TYPE="STUDY">Tedman 1997</LINK>). Depression was shown to be associated a significantly reduced quality of life in ALS (<LINK REF="REF-Lou-2003" TYPE="REFERENCE">Lou 2003</LINK>). Furthermore, suffering was statistically correlated with increasing pain, and pain was the most significant contributor to suffering in the final stages of disease (<LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>). There was a marked interference of pain with activities of daily living in ALS patients (<LINK REF="STD-Jensen-2005" TYPE="STUDY">Jensen 2005</LINK>). In the final stages of disease, pain was associated with a patient's interest in assisted suicide (<LINK REF="STD-Ganzini-2002b" TYPE="STUDY">Ganzini 2002b</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Causes and localisation of pain</HEADING>
<P>Most frequently, pain was found to be associated with reduced joint mobility, cramps or skin pressure caused by immobility (Borasio 1997; Borasio 2001b; <LINK REF="STD-de-Castro_x002d_Costa-1999" TYPE="STUDY">de Castro-Costa 1999</LINK>; <LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>; <LINK REF="STD-Neudert-2001" TYPE="STUDY">Neudert 2001</LINK>; <LINK REF="STD-Newrick-1984" TYPE="STUDY">Newrick 1984</LINK>). There were also case reports of a chronic central pain syndrome in ALS (<LINK REF="STD-Drake-1983" TYPE="STUDY">Drake 1983</LINK>) as well as a case of complex regional pain syndrome (CRPS) in an ALS patient without preceding trauma (<LINK REF="STD-Shibata-2003" TYPE="STUDY">Shibata 2003</LINK>). Pain was most frequently localised in the lower back area, the legs, and in the shoulder and neck area of the patients (<LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>; <LINK REF="STD-Newrick-1985" TYPE="STUDY">Newrick 1985</LINK>; <LINK REF="STD-Saunders-1981" TYPE="STUDY">Saunders 1981</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Therapy for pain</HEADING>
<P>Acetaminophen or other NSAIDs were usually applied as first line treatment for pain in ALS (<LINK REF="STD-Saunders-1981" TYPE="STUDY">Saunders 1981</LINK>; <LINK REF="STD-Wu-1998" TYPE="STUDY">Wu 1998</LINK>). Pain was often shown to be well controlled by these drugs in the earlier stages of disease (<LINK REF="STD-Saunders-1981" TYPE="STUDY">Saunders 1981</LINK>). However, there was evidence that in the later stages of disease pain may not be controlled with these analgesics (<LINK REF="STD-Newrick-1984" TYPE="STUDY">Newrick 1984</LINK>).<BR/>
<BR/>Although pain was shown to be common, especially in the later stages of disease, it was found to be frequently undertreated (<LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>; <LINK REF="STD-Mandler-2001" TYPE="STUDY">Mandler 2001</LINK>). In a study by Ganzini and colleagues, only 77% of patients with pain received a specific treatment (<LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>). These patients were treated with opioids in 40%, NSAIDs in 44% and acetaminophen in 19% (<LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>).<BR/>
<BR/>Opioids were found to be an effective therapy for pain, which also showed beneficial effects on dyspnoea and insomnia (<LINK REF="STD-O_x0027_Brien-1992" TYPE="STUDY">O'Brien 1992</LINK>) (mean dose 30 (+/- 2.34) mg/24 hour oral morphine equivalent, mean duration of treatment 58 (+/- 18.51) days). Opioids were significantly more likely to be administered if patients were treated in a hospice or palliative care unit compared to those treated at home (<LINK REF="STD-Neudert-2001" TYPE="STUDY">Neudert 2001</LINK>; <LINK REF="STD-Oliver-1996" TYPE="STUDY">Oliver 1996</LINK>; <LINK REF="STD-Saunders-1981" TYPE="STUDY">Saunders 1981</LINK>). There were distinct inter-country differences regarding the use of opioids: Neudert and colleagues observed morphine to be given to only 27% of a German ALS cohort as compared to 82% of a comparable UK cohort (<LINK REF="STD-Neudert-2001" TYPE="STUDY">Neudert 2001</LINK>). A study in which oral morphine was used over an average of 95 days suggested that strong opioids could be used safely in palliative care and do not necessarily shorten life (<LINK REF="STD-Oliver-1998" TYPE="STUDY">Oliver 1998</LINK>). One study reported that cannabis was effective at reducing pain in ALS (<LINK REF="STD-Amtmann-2004" TYPE="STUDY">Amtmann 2004</LINK>). However, only about 10% of ALS patients surveyed in this study reported using cannabis, distinctly fewer than observed in other severe diseases, such as multiple sclerosis, AIDS or cancer patients (<LINK REF="STD-Amtmann-2004" TYPE="STUDY">Amtmann 2004</LINK>).<BR/>
<BR/>Quinine may be an option for the treatment of muscle cramps in ALS in many countries, but is no longer approved for therapy of cramps in the United States as determined by the US Food and Drug Administration (<LINK REF="REF-FDA-2006" TYPE="REFERENCE">FDA 2006</LINK>; <LINK REF="REF-FDA-2010" TYPE="REFERENCE">FDA 2010</LINK>). A survey of members of the European ALS Research Group showed that for treatment of cramps, quinine sulphate was used in 58% of centres, benzodiazepines in 40%, magnesium in 25% and carbamazepine in 23% (<LINK REF="STD-Borasio-2001a" TYPE="STUDY">Borasio 2001a</LINK>). Separate Cochrane reviews on quinine for the treatment of muscle cramps (<LINK REF="REF-El-Tawil-2010" TYPE="REFERENCE">El Tawil 2010</LINK>) and treatment for muscle cramps in ALS (<LINK REF="REF-Baldinger-2012" TYPE="REFERENCE">Baldinger 2012</LINK>) have been published. Gabapentin (<LINK REF="REF-Miller-2001" TYPE="REFERENCE">Miller 2001</LINK>) and tetrahydrocannabinol (<LINK REF="STD-Weber-2010" TYPE="STUDY">Weber 2010</LINK>) were observed to have no significant effect on muscle cramps. In contrast, a small open-label, non-controlled study suggested that levetiracetam 1500 mg twice daily may be effective in reducing the severity and frequency of cramps in ALS (<LINK REF="STD-Bedlack-2009" TYPE="STUDY">Bedlack 2009</LINK>). So far, there have been no randomised trials examining the effectiveness of the existing anti-spasticity drugs in ALS (Ashworth 2006). According to a survey of expert opinion, as a therapy for spasticity, baclofen was used in 100% of large centres, tizanidine in 36%, benzodiazepines in 21% and dantrolene in 29% (<LINK REF="STD-Chio-2001" TYPE="STUDY">Chio 2001</LINK>). A survey of members of the European ALS Research Group showed that for the treatment of spasticity, carbamazepine was used in 93%, tizanidine in 38%, dantrolene in 36% and benzodiazepines in 36% (<LINK REF="STD-Borasio-2001a" TYPE="STUDY">Borasio 2001a</LINK>). The effectiveness of these drugs on spasticity-associated pain was not monitored in either study. In a case series of eight ALS patients with intractable pain related to spasticity, intrathecal baclofen was able to achieve a pain score reduction in six patients, indicating that intrathecal application of baclofen could be an option to treat spasticity-related pain in patients that do not respond to oral therapy (<LINK REF="STD-McClelland-2008" TYPE="STUDY">McClelland 2008</LINK>).</P>
<P>Though there is some evidence from animal models that riluzole could be beneficial in neuropathic pain (<LINK REF="REF-Coderre-2007" TYPE="REFERENCE">Coderre 2007</LINK>; <LINK REF="REF-Sung-2003" TYPE="REFERENCE">Sung 2003</LINK>), this has not been demonstrated in humans so far (<LINK REF="REF-Pittenger-2008" TYPE="REFERENCE">Pittenger 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Pain as an underrated symptom in ALS</HEADING>
<P>An important goal of treatment in patients with ALS is to relieve symptoms, diminish suffering and improve quality of life. The studies we reviewed showed pain in ALS to be common, especially in the later stages of disease and to have a pronounced influence on quality of life and suffering (<LINK REF="STD-Ganzini-1999" TYPE="STUDY">Ganzini 1999</LINK>; <LINK REF="STD-Ganzini-2002b" TYPE="STUDY">Ganzini 2002b</LINK>; <LINK REF="STD-Tedman-1997" TYPE="STUDY">Tedman 1997</LINK>). Treatment for pain, therefore, should be recognised as an important aspect of palliative care in ALS.<BR/>
<BR/>In contrast to its clinical relevance, data regarding the treatment for pain in ALS were found to be extremely scarce. As mentioned above, we found no randomised or quasi-randomised controlled trials or well-designed observational studies. This under-representation in the scientific literature in our opinion demonstrates that pain is still an underestimated symptom in ALS and may consequently be frequently undertreated.<BR/>
<BR/>We found data regarding pain in ALS not only to be scarce, but also frequently inconsistent when describing certain characteristics. For example, we found pronounced differences between studies describing the prevalence or severity of pain. These discrepancies may be partially due to differences among the cohorts included in the studies, for example, with regard to duration of disease.<BR/>
<BR/>Data regarding the effectiveness of different analgesics for therapy of pain in ALS were even rarer than data on the characteristics of pain in ALS or MND. The few available low evidence level studies seem to indicate that NSAIDs and acetaminophen, or both, may be effective for moderate pain frequently observed in the earlier stages of disease (<LINK REF="STD-Saunders-1981" TYPE="STUDY">Saunders 1981</LINK>; <LINK REF="STD-Wu-1998" TYPE="STUDY">Wu 1998</LINK>). However, if these therapies prove to be insufficient, opioids seem to be an effective and well-tolerated alternative that could also alleviate other symptoms such as dyspnoea and anxiety (<LINK REF="STD-Neudert-2001" TYPE="STUDY">Neudert 2001</LINK>; <LINK REF="STD-O_x0027_Brien-1992" TYPE="STUDY">O'Brien 1992</LINK>; <LINK REF="STD-Oliver-1998" TYPE="STUDY">Oliver 1998</LINK>).</P>
<P>Treatment for pain in ALS is a common unresolved problem. In the absence of any evidence from randomised controlled trials, it is the authors' opinion that treatment for pain in ALS should follow the 1990 World Health Organization (WHO) Analgesic Ladder (<LINK REF="REF-WHO-1990" TYPE="REFERENCE">WHO 1990</LINK>). The WHO Analgesic Ladder includes a structured approach to the management of pain according to pain severity and the corresponding need for utilisation of drugs with the increasing potency required for effective pain control. The Analgesic Ladder includes the major categories of analgesic agents that this review has identified as being in use for patients with ALS or MND. The recommendation for using the WHO Analgesic Ladder is also consistent with the overall symptom management goals discussed in the evidence-based practice parameter for care of the patient with ALS developed by the American Academy of Neurology (<LINK REF="REF-Miller-1999" TYPE="REFERENCE">Miller 1999</LINK>).</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-08-25 10:36:39 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-04-30 10:20:10 +0100" MODIFIED_BY="Kate Jewitt">
<P>There is no evidence from randomised controlled trials about the management of pain in ALS.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-08-25 10:36:39 +0100" MODIFIED_BY="[Empty name]">
<P>Further research on this important aspect of palliative care in ALS is needed. Randomised controlled trials should be initiated to determine the effectiveness of different analgesics for the treatment of pain in ALS. Treatment of pain should be included as an outcome measure in clinical trials using drugs with a known analgesic capacity. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-04-30 09:51:56 +0100" MODIFIED_BY="Ruth Brassington">
<P>The authors thank Ms Kate Jewitt, Ms Janice Fernandes and Mrs Rachel Barton for their invaluable support for this review. The Cochrane Neuromuscular Disease Group editorial base carried out searches.</P>
<P>The editorial base of the Cochrane Neuromuscular Disease Group is supported by the Motor Neuron Disease Association and the MRC Centre for Neuromuscular Disease.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-05-10 14:59:10 +0100" MODIFIED_BY="Ruth Brassington">
<P>JB, JK: none known</P>
<P>AL and his institution has received research and other support from various sources, as follows, but none related to this review. AL has received lecture or consulting fees, travel support or honoraria from Biogen Idec, Merz Pharma, Nutricia, Novartis, Thierry Latran Foundation, Stifterverband; board membership fees from Biogen Idec; and fees for expert testimony from Teva. His institution has grants or grants pending from Biogen Idec, GSK, Teva, Merz Pharma. Royalties have been paid to AL or his institution from Thieme Verlag, Cambridge University Press.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>JB wrote the first draft of the manuscript and dealt with peer review revisions. AL, JK and JDM commented on drafts and agreed the final version of the review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-04-30 09:52:00 +0100" MODIFIED_BY="[Empty name]">
<P>'Risk of bias' methodology updated. For the current update, we included searches for ongoing trials. We also included a clarification that studies of treatments for cramps are not included in the review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-04-30 09:59:19 +0100" MODIFIED_BY="Kate Jewitt">
<STUDIES MODIFIED="2013-04-30 09:52:26 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES MODIFIED="2013-04-30 09:52:26 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abe-2008" MODIFIED="2013-04-17 10:21:32 +0100" MODIFIED_BY="Ruth Brassington" NAME="Abe 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-04-17 10:21:32 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abe Y, Miyashita M, Ito N, Shirai Y, Momose Y, Ichikawa Y, et al</AU>
<TI>Attitude of outpatients with neuromuscular diseases in Japan to pain and use of analgesics</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2008</YR>
<VL>267</VL>
<NO>1-2</NO>
<PG>22-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="17916366"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Adelman-2004" MODIFIED="2010-08-25 10:38:22 +0100" MODIFIED_BY="[Empty name]" NAME="Adelman 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-08-25 10:38:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adelman EE, Albert SM, Rabkin JG, Del Bene ML, Tider T, O'Sullivan I</AU>
<TI>Disparities in perceptions of distress and burden in ALS patients and family caregivers</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>62</VL>
<NO>10</NO>
<PG>1766-70</PG>
<IDENTIFIERS MODIFIED="2010-08-17 10:44:53 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 10:44:53 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="15159475"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amtmann-2004" MODIFIED="2010-08-17 10:46:44 +0100" MODIFIED_BY="Angela Gunn" NAME="Amtmann 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-08-17 10:46:44 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amtmann D, Weydt P, Johnson KL, Jensen MP, Carter GT</AU>
<TI>Survey of cannabis use in patients with amyotrophic lateral sclerosis</TI>
<SO>American Journal of Hospice and Palliative Care</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>2</NO>
<PG>95-104</PG>
<IDENTIFIERS MODIFIED="2010-08-17 10:46:44 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 10:46:44 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="15055508"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bedlack-2009" MODIFIED="2010-08-25 10:38:00 +0100" MODIFIED_BY="[Empty name]" NAME="Bedlack 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-08-25 10:38:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bedlack RS, Pastula DM, Hawes J, Heydt D</AU>
<TI>Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease</TI>
<SO>Amyotrophic Lateral Sclerosis</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>4</NO>
<PG>210-5</PG>
<IDENTIFIERS MODIFIED="2010-07-23 15:55:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18821142"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borasio-2001a" MODIFIED="2010-08-17 10:52:25 +0100" MODIFIED_BY="Angela Gunn" NAME="Borasio 2001a" YEAR="2001">
<REFERENCE MODIFIED="2010-08-17 10:52:25 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borasio GD, Shaw PJ, Hardiman O, Ludolph AC, Sales Luis ML, Silani V; European ALS Study Group</AU>
<TI>Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>3</NO>
<PG>159-64</PG>
<IDENTIFIERS MODIFIED="2010-08-17 10:52:25 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 10:52:25 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="11771773"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bradley-2001" MODIFIED="2010-08-25 10:38:48 +0100" MODIFIED_BY="[Empty name]" NAME="Bradley 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-08-25 10:38:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bradley WG, Anderson F, Bromberg M, Gutmann L, Harati Y, Ross M, et al, ALS CARE Study Group</AU>
<TI>Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. The American Academy of Neurology</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>3</NO>
<PG>500-4</PG>
<IDENTIFIERS MODIFIED="2010-08-17 10:55:32 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 10:55:32 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="11502920"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-2010" MODIFIED="2013-04-17 10:22:41 +0100" MODIFIED_BY="Ruth Brassington" NAME="Carter 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-04-17 10:22:41 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter GT, Abood ME, Aggarwal SK, Weiss MD</AU>
<TI>Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials</TI>
<SO>The American Journal of Hospice and Palliative Care</SO>
<YR>2010</YR>
<VL>27</VL>
<NO>5</NO>
<PG>347-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="20439484"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chio-2001" MODIFIED="2010-08-17 10:56:51 +0100" MODIFIED_BY="Angela Gunn" NAME="Chio 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-08-17 10:56:51 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiò A, Silani V; Italian ALS Study Group</AU>
<TI>Amyotrophic lateral sclerosis care in Italy: a nationwide study in neurological centers</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2001</YR>
<VL>191</VL>
<NO>1-2</NO>
<PG>145-50</PG>
<IDENTIFIERS MODIFIED="2010-08-17 10:56:51 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 10:56:51 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="11677006"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Carvalho-2001" MODIFIED="2010-08-17 10:57:44 +0100" MODIFIED_BY="Angela Gunn" NAME="de Carvalho 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-08-17 10:57:44 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Carvalho M</AU>
<TI>Gabapentin for the treatment of spasticity in patients with amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>1</NO>
<PG>47-8</PG>
<IDENTIFIERS MODIFIED="2010-08-17 10:57:44 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 10:57:44 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="11465933"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Castro_x002d_Costa-1999" MODIFIED="2010-08-17 10:59:10 +0100" MODIFIED_BY="Angela Gunn" NAME="de Castro-Costa 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-08-17 10:59:10 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Castro-Costa CM, Oria RB, Machado-Filho JA, Franco MT, Diniz DL, Giffoni SD, et al</AU>
<TI>Amyotrophic lateral sclerosis. Clinical analysis of 78 cases from Fortaleza (northeastern Brazil)</TI>
<SO>Arquivos de Neuro-Psiquiatria</SO>
<YR>1999</YR>
<VL>57</VL>
<NO>3B</NO>
<PG>761-74</PG>
<IDENTIFIERS MODIFIED="2010-08-17 10:59:10 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 10:59:10 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="10751910"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drake-1983" MODIFIED="2010-08-17 11:00:12 +0100" MODIFIED_BY="Angela Gunn" NAME="Drake 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-08-17 11:00:12 +0100" MODIFIED_BY="Angela Gunn" NOTES="&lt;p&gt;Drake 1983&lt;br&gt;Drake ME. Chronic pain syndrome in Amyotrophic lateral sclerosis. Archives of Neurology 1983; 40(7): 453-4.&lt;/p&gt;" NOTES_MODIFIED="2010-08-17 11:00:12 +0100" NOTES_MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drake ME Jr</AU>
<TI>Chronic pain syndrome in amyotrophic lateral sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1983</YR>
<VL>40</VL>
<NO>7</NO>
<PG>453-4</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:00:12 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:00:12 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE=" 6860189"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Forshew-2003" MODIFIED="2010-08-17 11:01:09 +0100" MODIFIED_BY="Angela Gunn" NAME="Forshew 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-08-17 11:01:09 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forshew DA, Bromberg MB</AU>
<TI>A survey of clinicians' practice in the symptomatic treatment of ALS</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>4</NO>
<PG>258-63</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:01:09 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:01:09 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="14753660"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganzini-1998" MODIFIED="2010-08-17 11:02:18 +0100" MODIFIED_BY="Angela Gunn" NAME="Ganzini 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-08-17 11:02:18 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganzini L, Johnston WS, McFarland BH, Tolle SW, Lee MA</AU>
<TI>Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>14</NO>
<PG>967-73</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:02:18 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:02:18 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="9753713"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganzini-1999" MODIFIED="2010-08-17 11:03:07 +0100" MODIFIED_BY="Angela Gunn" NAME="Ganzini 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-08-17 11:03:07 +0100" MODIFIED_BY="Angela Gunn" NOTES="&lt;p&gt;Ganzini 1999&lt;br&gt;Ganzini L, Johnston WS, Hoffman WF. Correlates of suffering in amyotrophic lateral sclerosis. Neurology 1999; 52(7): 1434-40.&lt;/p&gt;" NOTES_MODIFIED="2010-08-17 11:03:07 +0100" NOTES_MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganzini L, Johnston WS, Hoffman WF</AU>
<TI>Correlates of suffering in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>7</NO>
<PG>1434-40</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:03:07 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:03:07 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="10227631"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganzini-2002a" MODIFIED="2010-08-17 11:04:21 +0100" MODIFIED_BY="Angela Gunn" NAME="Ganzini 2002a" YEAR="2002">
<REFERENCE MODIFIED="2010-08-17 11:04:21 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganzini L, Silveira MJ, Johnston WS</AU>
<TI>Predictors and correlates of interest in assisted suicide in the final month of life among ALS patients in Oregon and Washington</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>3</NO>
<PG>312-7</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:04:21 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:04:21 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="12458112"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganzini-2002b" MODIFIED="2010-08-17 11:05:25 +0100" MODIFIED_BY="Angela Gunn" NAME="Ganzini 2002b" YEAR="2002">
<REFERENCE MODIFIED="2010-08-17 11:05:25 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganzini L, Johnston WS, Silveira MJ</AU>
<TI>The final month of life in patients with ALS</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>3</NO>
<PG>428-31</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:05:25 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:05:25 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="12177378"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hecht-2002" MODIFIED="2010-08-17 11:06:28 +0100" MODIFIED_BY="Angela Gunn" NAME="Hecht 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-08-17 11:06:28 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hecht M, Hillemacher T, Gräsel E, Tigges S, Winterholler M, Heuss D, et al</AU>
<TI>Subjective experience and coping in ALS</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>4</NO>
<PG>225-31</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:06:28 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:06:28 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="12710513"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen-2005" MODIFIED="2010-08-17 11:07:28 +0100" MODIFIED_BY="Angela Gunn" NAME="Jensen 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-08-17 11:07:28 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jensen MP, Abresch RT, Carter GT, McDonald CM</AU>
<TI>Chronic pain in persons with neuromuscular disease</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>2005</YR>
<VL>86</VL>
<NO>6</NO>
<PG>1155-63</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:07:28 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:07:28 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="15954054"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maessen-2010" MODIFIED="2013-04-17 10:22:50 +0100" MODIFIED_BY="Ruth Brassington" NAME="Maessen 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-04-17 10:22:50 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maessen M, Veldink JH, van den Berg LH, Schouten HJ, van der Wal G, Onwuteaka-Philipsen BD</AU>
<TI>Requests for euthanasia: origin of suffering in ALS, heart failure, and cancer patients</TI>
<SO>Journal of Neurology</SO>
<YR>2010</YR>
<VL>257</VL>
<NO>7</NO>
<PG>1192-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="20148336"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mandler-2001" MODIFIED="2010-08-17 11:08:39 +0100" MODIFIED_BY="Angela Gunn" NAME="Mandler 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-08-17 11:08:39 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandler RN, Anderson FA Jr, Miller RG, Clawson L, Cudkowicz M, Del Bene M; ALS C.A.R.E. Study Group</AU>
<TI>The ALS Patient Care Database: insights into end-of-life care in ALS</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>4</NO>
<PG>203-8</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:08:39 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:08:39 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE=" 11958732"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McClelland-2008" MODIFIED="2010-08-25 10:39:08 +0100" MODIFIED_BY="[Empty name]" NAME="McClelland 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-08-25 10:39:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McClelland S 3rd, Bethoux FA, Boulis NM, Sutliff MH, Stough DK, Schwetz KM, et al</AU>
<TI>Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief</TI>
<SO>Muscle and Nerve</SO>
<YR>2008</YR>
<VL>37</VL>
<NO>3</NO>
<PG>396-8</PG>
<IDENTIFIERS MODIFIED="2010-07-23 13:10:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="17894358"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neudert-2001" MODIFIED="2010-08-17 11:10:50 +0100" MODIFIED_BY="Angela Gunn" NAME="Neudert 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-08-17 11:10:50 +0100" MODIFIED_BY="Angela Gunn" NOTES="&lt;p&gt;Neudert 2001&lt;br&gt;Neudert C, Oliver D, Wasner M, Borasio GD. The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol 2001; 248(7): 612-6.&lt;/p&gt;" NOTES_MODIFIED="2010-08-17 11:10:50 +0100" NOTES_MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neudert C, Oliver D, Wasner M, Borasio GD</AU>
<TI>The course of the terminal phase in patients with amyotrophic lateral sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>2001</YR>
<VL>248</VL>
<NO>7</NO>
<PG>612-6</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:10:50 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:10:50 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="11518004"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newrick-1984" MODIFIED="2010-08-25 10:39:24 +0100" MODIFIED_BY="[Empty name]" NAME="Newrick 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-08-25 10:39:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Newrick 1984&lt;br&gt;Newrick PG, Langton-Hewer R. Motor neuron disease: can we do better? British Medical Journal 1984; 289(6444): 539-42.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-08-25 10:39:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newrick PG, Langton-Hewer R</AU>
<TI>Motor neurone disease: can we do better? A study of 42 patients</TI>
<SO>British Medical Journal</SO>
<YR>1984</YR>
<VL>289</VL>
<NO>6444</NO>
<PG>539-42</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:11:58 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:11:58 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="6235890"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newrick-1985" MODIFIED="2010-08-17 11:12:39 +0100" MODIFIED_BY="Angela Gunn" NAME="Newrick 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-08-17 11:12:39 +0100" MODIFIED_BY="Angela Gunn" NOTES="&lt;p&gt;Newrick 1985&lt;br&gt;Newrick PG, Langton-Hewer R. Pain in motor neuron disease. Journal of Neurology, Neurosurgery and Psychiatry 1985; 48(8): 838-40.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-08-17 11:12:39 +0100" NOTES_MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newrick PG, Langton-Hewer R</AU>
<TI>Pain in motor neuron disease</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1985</YR>
<VL>48</VL>
<NO>8</NO>
<PG>838-40</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:12:39 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:12:39 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="4031936"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Brien-1992" MODIFIED="2010-08-17 11:13:26 +0100" MODIFIED_BY="Angela Gunn" NAME="O'Brien 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-08-17 11:13:26 +0100" MODIFIED_BY="Angela Gunn" NOTES="&lt;p&gt;O'Brien 1992&lt;br&gt;O'Brien T, Kelly M, Sunders C. Motor neuron disease: a hospice perspective. British Medical Journal 1992; 304: 471-473.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-08-17 11:13:26 +0100" NOTES_MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien T, Kelly M, Saunders C</AU>
<TI>Motor neuron disease: a hospice perspective</TI>
<SO>BMJ</SO>
<YR>1992</YR>
<VL>304</VL>
<NO>6825</NO>
<PG>471-3</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:13:26 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:13:26 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="1547416"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oliver-1996" MODIFIED="2010-08-17 11:14:48 +0100" MODIFIED_BY="Angela Gunn" NAME="Oliver 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-08-17 11:14:48 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oliver D</AU>
<TI>The quality of care and symptom control - the effects on the terminal phase of ALS/MND</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1996</YR>
<VL>139 Suppl</VL>
<PG>134-6</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:14:48 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:14:48 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="8899674"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oliver-1998" MODIFIED="2010-08-17 11:15:37 +0100" MODIFIED_BY="Angela Gunn" NAME="Oliver 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-08-17 11:15:37 +0100" MODIFIED_BY="Angela Gunn" NOTES="&lt;p&gt;Oliver 1998&lt;br&gt;Oliver D. Opioid medication in the palliative care of motor neuron disease. Palliative Medicine 1998; 12(2): 113-5.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-08-17 11:15:37 +0100" NOTES_MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oliver D</AU>
<TI>Opioid medication in the palliative care of motor neurone disease</TI>
<SO>Palliative Medicine</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>2</NO>
<PG>113-5</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:15:37 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:15:37 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="9616447"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saunders-1981" MODIFIED="2010-08-25 10:39:42 +0100" MODIFIED_BY="[Empty name]" NAME="Saunders 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-08-25 10:39:42 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Saunders 1981&lt;br&gt;Saunders DC, Walsh TD, Smith M. Hospice care in motor neuron disease. in: Saunders C, Summers DH, Teller N, eds. The living idea. London: Edward Arnold 1981&lt;/p&gt;" NOTES_MODIFIED="2010-08-25 10:39:42 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Saunders C, Walsh TD, Smith M</AU>
<TI>Hospice care in motor neuron disease</TI>
<SO>Hospice: The Living Idea</SO>
<YR>1981</YR>
<ED>Saunders C, Summers DH, Teller N</ED>
<PB>Edward Arnold</PB>
<CY>London</CY>
<IDENTIFIERS MODIFIED="2010-08-17 11:31:43 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:31:43 +0100" MODIFIED_BY="Angela Gunn" TYPE="OTHER" VALUE="0713143983"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shibata-2003" MODIFIED="2010-08-17 11:34:30 +0100" MODIFIED_BY="Angela Gunn" NAME="Shibata 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-08-17 11:34:30 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shibata M, Abe K, Jimbo A, Shimizu T, Mihara M, Sadahiro S, et al</AU>
<TI>Complex regional pain syndrome type I associated with amyotrophic lateral sclerosis</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>1</NO>
<PG>69-70</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:34:30 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:34:30 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="12514459"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tedman-1997" MODIFIED="2010-08-17 11:35:41 +0100" MODIFIED_BY="Angela Gunn" NAME="Tedman 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-08-17 11:35:41 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tedman BM, Young CA, Williams IR</AU>
<TI>Assessment of depression in patients with motor neuron disease and other neurologically disabling illness</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1997</YR>
<VL>152</VL>
<NO>Suppl 1</NO>
<PG>S75-9</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:35:41 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:35:41 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="9419059"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trail-2003" MODIFIED="2010-08-17 11:36:49 +0100" MODIFIED_BY="Angela Gunn" NAME="Trail 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-08-17 11:36:49 +0100" MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trail M, Nelson ND, Van JN, Appel SH, Lai EC</AU>
<TI>A study comparing patients with amyotrophic lateral sclerosis and their caregivers on measures of quality of life, depression, and their attitudes toward treatment options</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2003</YR>
<VL>209</VL>
<NO>1-2</NO>
<PG>79-85</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:36:49 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:36:49 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="12686407"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weber-2010" MODIFIED="2013-04-30 09:52:26 +0100" MODIFIED_BY="Ruth Brassington" NAME="Weber 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-04-30 09:52:26 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weber M, Goldman B, Truniger S</AU>
<TI>Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>2010</YR>
<VL>81</VL>
<NO>10</NO>
<PG>1135-40</PG>
<IDENTIFIERS MODIFIED="2013-04-15 13:57:14 +0100" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2013-04-15 13:57:14 +0100" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="20498181"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winter-2010" MODIFIED="2013-04-17 10:22:34 +0100" MODIFIED_BY="Ruth Brassington" NAME="Winter 2010" YEAR="2010 Apr 10 [Epub ahead of print]">
<REFERENCE MODIFIED="2013-04-17 10:22:34 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winter Y, Schepelmann K, Spottke AE, Claus D, Grothe C, Schröder R, et al</AU>
<TI>Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy</TI>
<SO>Journal of Neurology</SO>
<YR>2010 Apr 10 [Epub ahead of print]</YR>
<VL>257</VL>
<NO>9</NO>
<PG>1473-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="20383521"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-1998" MODIFIED="2010-08-17 11:38:05 +0100" MODIFIED_BY="Angela Gunn" NAME="Wu 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-08-17 11:38:05 +0100" MODIFIED_BY="Angela Gunn" NOTES="&lt;p&gt;Wu 1998&lt;br&gt;Wu PY. The Management of Patients with Advanced Motor Neuron Disease. Zhonghua Yi Xue Za Zhi (Taipei) 1998; 61(3): 141-5.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-08-17 11:38:05 +0100" NOTES_MODIFIED_BY="Angela Gunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu PY</AU>
<TI>The management of patients with advanced motor neuron disease</TI>
<SO>Zhonghua Yi Xue Za Zhi</SO>
<YR>1998</YR>
<VL>61</VL>
<NO>3</NO>
<PG>141-5</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:38:05 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:38:05 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="9556945"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-04-30 09:59:19 +0100" MODIFIED_BY="Kate Jewitt">
<ADDITIONAL_REFERENCES MODIFIED="2013-04-30 09:59:19 +0100" MODIFIED_BY="Kate Jewitt">
<REFERENCE ID="REF-Ashworth-2006" MODIFIED="2013-04-17 10:41:11 +0100" MODIFIED_BY="Ruth Brassington" NAME="Ashworth 2006" TYPE="COCHRANE_REVIEW">
<AU>Ashworth NL, Satkunam LE, Deforge D</AU>
<TI>Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004156.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Baldinger-2012" MODIFIED="2013-04-30 09:58:53 +0100" MODIFIED_BY="Kate Jewitt" NAME="Baldinger 2012" TYPE="COCHRANE_REVIEW">
<AU>Baldinger R, Katzberg HD, Weber M</AU>
<TI>Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-04-11 16:17:45 +0100" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2013-04-11 16:17:45 +0100" MODIFIED_BY="Kate Jewitt" TYPE="DOI" VALUE="10.1002/14651858.CD004157.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Borasio-1997" MODIFIED="2013-04-17 10:37:37 +0100" MODIFIED_BY="Ruth Brassington" NAME="Borasio 1997" NOTES="&lt;p&gt;Borasio 1997&lt;br&gt;Borasio GD, Voltz R. Palliative care in amyotrophic lateral sclerosis. Journal of Neurology 1997; 244 (Suppl. 4): 11-17.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-04-17 10:37:37 +0100" NOTES_MODIFIED_BY="Ruth Brassington" TYPE="JOURNAL_ARTICLE">
<AU>Borasio GD, Voltz R</AU>
<TI>Palliative care in amyotrophic lateral sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>1997</YR>
<VL>244</VL>
<NO>Suppl 4</NO>
<PG>S11-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="9402548"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Borasio-2001b" MODIFIED="2013-04-17 10:46:17 +0100" MODIFIED_BY="Ruth Brassington" NAME="Borasio 2001b" NOTES="&lt;p&gt;Borasio 2001&lt;br&gt;Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. Neurologic Clinics 2001; 19 (4): 829-47.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-04-17 10:46:17 +0100" NOTES_MODIFIED_BY="Ruth Brassington" TYPE="JOURNAL_ARTICLE">
<AU>Borasio GD, Voltz R, Miller RG</AU>
<TI>Palliative care in amyotrophic lateral sclerosis</TI>
<SO>Neurologic Clinics</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>4</NO>
<PG>829-47</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="11854102"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brooks-2000" MODIFIED="2010-08-25 10:40:11 +0100" MODIFIED_BY="[Empty name]" NAME="Brooks 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases</AU>
<TI>El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2000</YR>
<VL>1</VL>
<NO>5</NO>
<PG>293-9</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:41:59 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:41:59 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="11464847"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brownell-1970" MODIFIED="2010-08-17 11:43:14 +0100" MODIFIED_BY="Angela Gunn" NAME="Brownell 1970" TYPE="JOURNAL_ARTICLE">
<AU>Brownell B, Oppenheimer DR, Hughes JT</AU>
<TI>The central nervous system in motor neurone disease</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1970</YR>
<VL>33</VL>
<NO>3</NO>
<PG>338-57</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:43:14 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:43:14 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="5431724"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2005" MODIFIED="2010-08-25 10:40:38 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 2005" TYPE="JOURNAL_ARTICLE">
<AU>Clarke DM, McLeod JE, Smith GC, Trauer T, Kissane DW</AU>
<TI>A comparison of psychosocial and physical functioning in patients with motor neurone disease and metastatic cancer</TI>
<SO>Journal of Palliative Care</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>3</NO>
<PG>173-9</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:45:45 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:45:45 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="16334972"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Coderre-2007" MODIFIED="2010-08-25 10:40:55 +0100" MODIFIED_BY="[Empty name]" NAME="Coderre 2007" TYPE="JOURNAL_ARTICLE">
<AU>Coderre TJ, Kumar N, Lefebvre CD, Yu JS</AU>
<TI>A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain</TI>
<SO>Journal of Neurochemistry</SO>
<YR>2007</YR>
<VL>100</VL>
<NO>5</NO>
<PG>1289-99</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:46:42 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:46:42 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="17241130"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Drory-2001" MODIFIED="2010-08-17 11:47:49 +0100" MODIFIED_BY="Angela Gunn" NAME="Drory 2001" TYPE="JOURNAL_ARTICLE">
<AU>Drory VE, Goltsman E, Reznik JG, Mosek A, Korczyn AD</AU>
<TI>The value of muscle exercise in patients with amyotrophic lateral sclerosis</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2001</YR>
<VL>191</VL>
<NO>1-2</NO>
<PG>133-7</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:47:49 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:47:49 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="11677004"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-El-Tawil-2010" MODIFIED="2013-04-30 09:59:19 +0100" MODIFIED_BY="Kate Jewitt" NAME="El Tawil 2010" TYPE="COCHRANE_REVIEW">
<AU>El-Tawil S, Al Musa T, Valli H, Lunn MPT, El-Tawil T, Weber M</AU>
<TI>Quinine for muscle cramps</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2013-04-15 13:11:46 +0100" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2013-04-15 13:11:46 +0100" MODIFIED_BY="Kate Jewitt" TYPE="DOI" VALUE="10.1002/14651858.CD005044.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-FDA-2006" MODIFIED="2013-04-30 09:53:30 +0100" MODIFIED_BY="Ruth Brassington" NAME="FDA 2006" TYPE="OTHER">
<AU>US Food and Drug Administration</AU>
<TI>FDA orders unapproved quinine drugs from the market and cautions consumers about 'off-label' use of quinine to treat leg cramps</TI>
<SO>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108799.htm</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2010" MODIFIED="2013-04-30 09:53:38 +0100" MODIFIED_BY="Ruth Brassington" NAME="FDA 2010" TYPE="OTHER">
<AU>US Food and Drug Administration</AU>
<TI>FDA Drug Safety Communication: new risk management plan and patient Medication Guide for Qualaquin (quinine sulfate)</TI>
<SO>http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218202.htm</SO>
<YR>2010 (accessed 17 April 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gubbay-1985" MODIFIED="2010-08-25 10:41:27 +0100" MODIFIED_BY="[Empty name]" NAME="Gubbay 1985" TYPE="JOURNAL_ARTICLE">
<AU>Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y</AU>
<TI>Amyotrophic lateral sclerosis. A study of its presentation and prognosis</TI>
<SO>Journal of Neurology</SO>
<YR>1985</YR>
<VL>232</VL>
<NO>5</NO>
<PG>295-300</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:49:03 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:49:03 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="4056836"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-04-30 09:54:27 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawyer-1953" MODIFIED="2010-08-17 11:57:29 +0100" MODIFIED_BY="Angela Gunn" NAME="Lawyer 1953" TYPE="JOURNAL_ARTICLE">
<AU>Lawyer TJr, Netsky MG</AU>
<TI>Amyotrophic lateral sclerosis</TI>
<SO>A. M. A. Archives of Neurology and Psychiatry</SO>
<YR>1953</YR>
<VL>69</VL>
<NO>2</NO>
<PG>171-92</PG>
<IDENTIFIERS MODIFIED="2010-08-17 11:57:29 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 11:57:29 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="13007227"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lou-2003" MODIFIED="2010-07-23 13:06:43 +0100" MODIFIED_BY="[Empty name]" NAME="Lou 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lou JS, Reeves A, Benice T, Sexton G</AU>
<TI>Fatigue and depression are associated with poor quality of life in ALS</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>122-3</PG>
<IDENTIFIERS MODIFIED="2010-07-23 13:06:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="12525733"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miller-1999" MODIFIED="2010-08-25 10:41:50 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 1999" TYPE="JOURNAL_ARTICLE">
<AU>Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, et al</AU>
<TI>Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>7</NO>
<PG>1311-23</PG>
<IDENTIFIERS MODIFIED="2010-08-17 12:28:49 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 12:28:49 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="10227612"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miller-2001" MODIFIED="2010-08-25 10:42:32 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 2001" TYPE="JOURNAL_ARTICLE">
<AU>Miller RG, Moore DH 2nd, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, et al; Western ALS Study Group</AU>
<TI>Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>7</NO>
<PG>843-8</PG>
<IDENTIFIERS MODIFIED="2010-08-17 12:30:14 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 12:30:14 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="11294919"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pittenger-2008" MODIFIED="2010-08-25 10:43:01 +0100" MODIFIED_BY="[Empty name]" NAME="Pittenger 2008" TYPE="JOURNAL_ARTICLE">
<AU>Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G</AU>
<TI>Riluzole in the treatment of mood and anxiety disorders</TI>
<SO>CNS Drugs</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>9</NO>
<PG>761-86</PG>
<IDENTIFIERS MODIFIED="2010-08-17 12:33:52 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 12:33:52 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="18698875"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-04-30 09:54:42 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan) [Computer Program]. Version 5.2</TI>
<YR>2012</YR>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sung-2003" MODIFIED="2010-08-25 10:43:13 +0100" MODIFIED_BY="[Empty name]" NAME="Sung 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sung B, Lim G, Mao J</AU>
<TI>Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats</TI>
<SO>Journal of Neuroscience</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>7</NO>
<PG>2899-910</PG>
<IDENTIFIERS MODIFIED="2010-07-23 13:31:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="12684477"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-1990" MODIFIED="2010-09-28 16:53:42 +0100" MODIFIED_BY="Kate Jewitt" NAME="WHO 1990" TYPE="OTHER">
<TI>Cancer pain relief and palliative care. Report of a WHO Expert Committee</TI>
<SO>World Health Organization Technical Report Series</SO>
<YR>1990</YR>
<VL>804</VL>
<PG>1-75</PG>
<IDENTIFIERS MODIFIED="2010-08-17 12:40:31 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 12:40:31 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="1702248"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Worms-2001" MODIFIED="2010-08-17 12:43:37 +0100" MODIFIED_BY="Angela Gunn" NAME="Worms 2001" TYPE="JOURNAL_ARTICLE">
<AU>Worms PM</AU>
<TI>The epidemiology of motor neuron diseases: a review of recent studies</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2001</YR>
<VL>191</VL>
<NO>1-2</NO>
<PG>3-9</PG>
<IDENTIFIERS MODIFIED="2010-08-17 12:43:37 +0100" MODIFIED_BY="Angela Gunn">
<IDENTIFIER MODIFIED="2010-08-17 12:43:37 +0100" MODIFIED_BY="Angela Gunn" TYPE="PUBMED" VALUE="11676986"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-04-30 09:55:31 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Brettschneider-2005" MODIFIED="2013-04-30 09:55:20 +0100" MODIFIED_BY="Ruth Brassington" NAME="Brettschneider 2005" TYPE="COCHRANE_PROTOCOL">
<AU>Brettschneider J, Ludolph A, Mitchell JD</AU>
<TI>Drug therapy for pain in amyotrophic lateral sclerosis/motor neuron disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-04-11 16:21:18 +0100" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2013-04-11 16:21:18 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD005226"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brettschneider-2008" MODIFIED="2013-04-30 09:55:31 +0100" MODIFIED_BY="Ruth Brassington" NAME="Brettschneider 2008" TYPE="COCHRANE_REVIEW">
<AU>Brettschneider J, Kurent J, Ludolph A, Mitchell J</AU>
<TI>Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-04-11 16:22:58 +0100" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2013-04-11 16:22:58 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD005226.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-04-30 09:52:05 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-04-30 09:52:05 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-04-30 09:52:02 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Abe-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-30 09:52:02 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Adelman-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Amtmann-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-23 15:55:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bedlack-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-23 15:55:40 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Borasio-2001a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bradley-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-30 09:52:03 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Carter-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-30 09:52:03 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chio-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Carvalho-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Castro_x002d_Costa-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Drake-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Forshew-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ganzini-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ganzini-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ganzini-2002a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ganzini-2002b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hecht-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jensen-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-30 09:52:03 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Maessen-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-30 09:52:03 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mandler-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-25 10:36:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McClelland-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-25 10:36:39 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Neudert-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Newrick-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Newrick-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Brien-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oliver-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oliver-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saunders-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shibata-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tedman-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Trail-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-30 09:52:04 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Weber-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-30 09:52:04 +0100" MODIFIED_BY="Ruth Brassington">
<P>A RCT of treatment for cramps in ALS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-30 09:52:05 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Winter-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-30 09:52:05 +0100" MODIFIED_BY="Ruth Brassington">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wu-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-04-14 14:38:11 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-04-30 09:55:01 +0100" MODIFIED_BY="Angela Gunn">
<APPENDIX ID="APP-01" MODIFIED="2012-07-03 09:33:25 +0100" MODIFIED_BY="Angela Gunn" NO="1">
<TITLE MODIFIED="2010-08-17 12:44:25 +0100" MODIFIED_BY="Angela Gunn">MEDLINE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-03 09:33:25 +0100" MODIFIED_BY="Angela Gunn">
<P>Database: Ovid MEDLINE(R) &lt;1946 to June Week 3 2012&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 randomized controlled trial.pt. (330201)<BR/>2 controlled clinical trial.pt. (84375)<BR/>3 randomized.ab. (233876)<BR/>4 placebo.ab. (132230)<BR/>5 drug therapy.fs. (1543331)<BR/>6 randomly.ab. (168558)<BR/>7 trial.ab. (242070)<BR/>8 groups.ab. (1106725)<BR/>9 or/1-8 (2867649)<BR/>10 (animals not (animals and humans)).sh. (3644610)<BR/>11 9 not 10 (2435542)<BR/>12 exp Motor Neuron Diseases/ (17466)<BR/>13 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease).mp. (5793)<BR/>14 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (64)<BR/>15 Amyotrophic Lateral Sclerosis.mp. (14118)<BR/>16 or/12-15 (21011)<BR/>17 (pain relie$ or pain therap$ or pain medicat$ or pain treat$ or analgesic$ or antiinflammatory agent or nsaid).mp. (114512)<BR/>18 exp Antiinflammatory Agents, Non-Steroidal/ (144357)<BR/>19 exp ANALGESICS/ (405157)<BR/>20 aspirin.tw. or ASPIRIN/ (48267)<BR/>21 salicylate.tw. or Salicylates/ (11649)<BR/>22 indomethacin.tw. or INDOMETHACIN/ (37834)<BR/>23 piroxicam.tw. or PIROXICAM/ (3162)<BR/>24 ketorolac.tw. or KETOROLAC/ (1856)<BR/>25 (tenoxicam or apazone or diclofenac or diflusinal or etodolac or fenoprofen or flurbiprofen or ibuprofen or ketoprofen or meclofenamate or nabumetone or naproxen or oxaprozin or phenylbutazone or sulindac or tolmetin or paracetamol or acetaminophen or APAP).mp. (48442)<BR/>26 exp NARCOTICS/ (81339)<BR/>27 (opioid$ or opiate$ or narcotic$).mp. (110252)<BR/>28 (morphinans or morphine or fentanyl or hydromorphone or oxycodone or pentazocine or methadone).mp. (72843)<BR/>29 codeine.tw. or CODEINE/ (5233)<BR/>30 (dihydrocodeine or dextromoramide or diamorphine or dextropropoxyphene or meptazinol or sufentanil or alfentanil or remifentanil or nalbuphine or dipipanone or pethidine or tramadol or buprenorphine).mp. (17410)<BR/>31 exp Antidepressive Agents, Tricyclic/ or (Tricyclic adj1 Antidepress$).tw. (31064)<BR/>32 (amitriptyline or desipramine or doxepine or clomipramine or levomepromazine or haloperidol or carbamazepine or gabapentin).mp. (50975)<BR/>33 exp Anesthesia Adjuvants/ (85623)<BR/>34 PAIN/pc, dt, th [Prevention and Control, Drug Therapy, Therapy] (30935)<BR/>35 or/17-34 (618590)<BR/>36 11 and 16 and 35 (151)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-07-03 09:45:48 +0100" MODIFIED_BY="Angela Gunn" NO="2">
<TITLE MODIFIED="2010-08-17 12:44:35 +0100" MODIFIED_BY="Angela Gunn">EMBASE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-03 09:45:48 +0100" MODIFIED_BY="Angela Gunn">
<P>Database: Embase &lt;1980 to 2012 Week 26&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 crossover-procedure.sh. (34246)<BR/>2 double-blind procedure.sh. (109462)<BR/>3 single-blind procedure.sh. (16047)<BR/>4 randomized controlled trial.sh. (324293)<BR/>5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (877566)<BR/>6 trial.ti. (132039)<BR/>7 or/1-6 (1004389)<BR/>8 (animal/ or nonhuman/ or animal experiment/) and human/ (1187619)<BR/>9 animal/ or nonanimal/ or animal experiment/ (3281792)<BR/>10 9 not 8 (2719455)<BR/>11 7 not 10 (920638)<BR/>12 limit 11 to embase (713539)<BR/>13 Motor Neuron Disease/ or Amyotrophic Lateral Sclerosis/ (22904)<BR/>14 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease).mp. (8463)<BR/>15 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (107)<BR/>16 amyotrophic lateral sclerosis.tw. (14103)<BR/>17 or/13-16 (25458)<BR/>18 (pain relie$ or pain therap$ or pain medicat$ or pain treat$ or analgesic$ or antiinflammatory agent or nsaid).mp. (250127)<BR/>19 exp Nonsteroidal Antiinflammatory Agent/ (377454)<BR/>20 exp ANALGESICS/ (566574)<BR/>21 aspirin.mp. or ASPIRIN/ (141880)<BR/>22 salicylate.mp. or Salicylates/ (21118)<BR/>23 indomethacin.mp. or INDOMETHACIN/ (67661)<BR/>24 piroxicam.mp. or PIROXICAM/ (9910)<BR/>25 ketorolac.mp. or KETOROLAC/ (7060)<BR/>26 (tenoxicam or apazone or diclofenac or diflusinal or etodolac or fenoprofen or flurbiprofen or ibuprofen or ketoprofen or meclofenamate or nabumetone or naproxen or oxaprozin or phenylbutazone or sulindac or tolmetin or paracetamol or acetaminophen or APAP).mp. (127135)<BR/>27 exp NARCOTICS/ (183153)<BR/>28 (opioid$ or opiate$ or narcotic$).mp. (142383)<BR/>29 (morphinans or morphine or fentanyl or hydromorphone or oxycodone or pentazocine or methadone).mp. (137993)<BR/>30 codeine.mp. or CODEINE/ (16242)<BR/>31 (dihydrocodeine or dextromoramide or diamorphine or dextropropoxyphene or meptazinol or sufentanil or alfentanil or remifentanil or nalbuphine or dipipanone or pethidine or tramadol or buprenorphine).mp. (70147)<BR/>32 exp Antidepressive Agents, Tricyclic/ or (Tricyclic adj1 Antidepress$).mp. (87917)<BR/>33 (amitriptyline or desipramine or doxepine or clomipramine or levomepromazine or haloperidol or carbamazepine or gabapentin).mp. (139460)<BR/>34 exp Anesthesia Adjuvants/ (650940)<BR/>35 PAIN/pc, dt, th [Prevention and Control, Drug Therapy, Therapy] (43081)<BR/>36 or/18-35 (1247542)<BR/>37 12 and 17 and 36 (229)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-07-03 09:50:32 +0100" MODIFIED_BY="Angela Gunn" NO="3">
<TITLE MODIFIED="2010-08-17 12:45:20 +0100" MODIFIED_BY="Angela Gunn">CINAHL (EBSCOhost) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-03 09:50:32 +0100" MODIFIED_BY="Angela Gunn">
<P>Tuesday, July 03, 2012 3:46:07 AM<BR/>
<BR/>S40 S38 and S39 6<BR/>S39 EM 201004- 815525<BR/>S38 S18 and S23 and S37 27<BR/>S37 S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 102707<BR/>S36 (MH "Pain/DT/PC/TH") 20767<BR/>S35 (MH "Anesthesia Adjuvants+") 7068<BR/>S34 amitriptyline or desipramine or doxepine or clomipramine or levomepromazine or haloperidol or carbamazepine or gabapentin or (antidepressive N3 tricyclic) 4968<BR/>S33 (MH "Antidepressive Agents, Tricyclic+") 2160<BR/>S32 dihydrocodeine or dextromoramide or diamorphine or dextropropoxyphene or meptazinol or sufentanil or alfentanil or remifentanil or nalbuphine or dipipanone or pethidine or tramadol or buprenorphine 3833<BR/>S31 morphinans or morphine or fentanyl or hydromorphone or oxycodone or pentazocine or methadone 11517<BR/>S30 opioid* or opiate* or narcotic* or codeine 19239<BR/>S29 (MH "Narcotics+") 20079<BR/>S28 tenoxicam or apazone or diclofenac or diflusinal or etodolac or fenoprofen or flurbiprofen or ibuprofen or ketoprofen or meclofenamate or nabumetone or naproxen or oxaprozin or phenylbutazone or sulindac or tolmetin or paracetamol or acetaminophen or APAP 6036<BR/>S27 aspirin or salicylic N2 acid or salicylate* or indomethacin or piroxicam or ketorolac 10101<BR/>S26 (MH "Analgesics+") 26665<BR/>S25 (MH "Antiinflammatory Agents, Non-Steroidal+") 17595<BR/>S24 pain N3 relief or pain N3 therap* or pain N3 treat* or analgesic* or antiinflammatory N3 agent* or nsaid 64781<BR/>S23 S19 or S20 or S21 or S22 4769<BR/>S22 (Lou Gehrig* W5 syndrome*) or (Lou Gehrig* w5 disease*) 30<BR/>S21 amyotrophic lateral sclerosis 1951<BR/>S20 motor neuron disease or motor neurone disease or motoneuron* disease or motorneuron* disease 465<BR/>S19 (MH "Motor Neuron Diseases+") 4516<BR/>S18 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 544729<BR/>S17 ABAB design* 76<BR/>S16 TI random* or AB random* 110869<BR/>S15 ( TI (cross?over or placebo* or control* or factorial or sham? or dummy) ) or ( AB (cross?over or placebo* or control* or factorial or sham? or dummy) ) 229065<BR/>S14 ( TI (clin* or intervention* or compar* or experiment* or preventive or therapeutic) or AB (clin* or intervention* or compar* or experiment* or preventive or therapeutic) ) and ( TI (trial*) or AB (trial*) ) 77341<BR/>S13 ( TI (meta?analys* or systematic review*) ) or ( AB (meta?analys* or systematic review*) ) 22527<BR/>S12 ( TI (single* or doubl* or tripl* or trebl*) or AB (single* or doubl* or tripl* or trebl*) ) and ( TI (blind* or mask*) or AB (blind* or mask*) ) 18089<BR/>S11 PT ("clinical trial" or "systematic review") 102544<BR/>S10 (MH "Factorial Design") 823<BR/>S9 (MH "Concurrent Prospective Studies") or (MH "Prospective Studies") 180529<BR/>S8 (MH "Meta Analysis") 14237<BR/>S7 (MH "Solomon Four-Group Design") or (MH "Static Group Comparison") 30<BR/>S6 (MH "Quasi-Experimental Studies") 5465<BR/>S5 (MH "Placebos") 7589<BR/>S4 (MH "Double-Blind Studies") or (MH "Triple-Blind Studies") 24428<BR/>S3 (MH "Clinical Trials+") 143550<BR/>S2 (MH "Crossover Design") 9355<BR/>S1 (MH "Random Assignment") or (MH "Random Sample") or (MH "Simple Random Sample") or (MH "Stratified Random Sample") or (MH "Systematic Random Sample") 56940</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-07-03 09:46:22 +0100" MODIFIED_BY="Angela Gunn" NO="4">
<TITLE MODIFIED="2010-08-17 12:44:46 +0100" MODIFIED_BY="Angela Gunn">AMED (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-03 09:46:22 +0100" MODIFIED_BY="Angela Gunn">
<P>Database: AMED (Allied and Complementary Medicine) &lt;1985 to June 2012&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 amyotrophic lateral sclerosis/ or motor neuron disease/ (256)<BR/>2 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease).mp. (163)<BR/>3 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (2)<BR/>4 Amyotrophic Lateral Sclerosis.mp. (245)<BR/>5 or/1-4 (383)<BR/>6 (pain relie$ or (pain adj2 treatment)).mp. (2378)<BR/>7 (nonsteroidal anti-inflammatory agent$ or nonsteroidal analgesic$ or anti-inflammatory agent$ or NSAID$ or aspirin or salicylate$ or indomethacin or piroxicam or ketorolac or tenoxicam or apazone or diclofenac or diflunisal or etodolac or fenoprofen or flurbiprofen or ibuprofen or ketoprofen or meclofenamate or nabumetone or naproxen or oxaprozin or phenylbutazone or sulindac or tolmetin or paracetamol or acetaminophen or APAP).mp. (1021)<BR/>8 exp Antiinflammatory agents/ (1657)<BR/>9 Narcotics/ (173)<BR/>10 exp Morphine/ (242)<BR/>11 exp Analgesics/ (1219)<BR/>12 (opioid$ or opiate$ or narcotic$ or morphinans or morphine or fentanyl or hydromorphone or oxycodone or pentazocine or methadone or codeine or dihydrocodeine or dextromoramide or diamorphine or dextropropoxyphene or meptazinol or sufentanil or alfentanil or remifentanil or nalbuphine or dipipanone or pethidine or tramadol or buprenorphine).mp. (1776)<BR/>13 or/6-12 (6277)<BR/>14 Pain/ (9274)<BR/>15 exp Therapy/ (31202)<BR/>16 14 and 15 (2030)<BR/>17 Antidepressive agents/ (239)<BR/>18 (amitriptyline or desipramine or doxepine or clomipramine or levomepromazine or haloperidol or carbamazepine or gabapentin).mp. (238)<BR/>19 or/13,16-18 (8225)<BR/>20 5 and 19 (8)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2010-05-18 16:45:11 +0100" MODIFIED_BY="Angela Gunn" NO="5">
<TITLE MODIFIED="2008-04-14 14:34:31 +0100" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-18 16:45:11 +0100" MODIFIED_BY="Angela Gunn">
<P>(Pt randomized controlled trial OR Pt controlled clinical trial OR Mh randomized controlled trials OR Mh random allocation OR Mh double-blind method OR Mh single-blind method) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Pt clinical trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$)) OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh placebos OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research design) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Ct comparative study OR Ex E05.337$ OR Mh follow-up studies OR Mh prospective studies OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animal AND NOT (Ct human and Ct animal))) [Words] [Words] and (moto$ neuron$ disease$ OR motoneuron$ disease$ OR Mh Motor Neuron Disease or MND OR Mh amyotrophic lateral sclerosis OR amyotroph$ OR ALS) [Words] [Words] and (pain relie$ OR pain therap$ OR pain medicat$ OR pain treat$ OR analgesic$ OR Mh analgesics OR anti-inflammatory agent$ OR NSAID OR aspirin OR salicylate OR indomethacin OR piroxicam OR ketorolac OR tenoxicam OR apazone OR diclofenac OR diflunisal OR etodolac OR fenoprofen OR flurbiprofen OR ibuprofen OR ketoprofen OR meclofenamate OR nabumetone OR naproxen OR oxaprozin OR phenylbutazone OR sulindac OR tolmetin OR paracetamol OR acetaminophen OR APAP OR opioid OR opiate OR narcotics OR morphinans OR morphine OR fentanyl OR hydromorphone OR oxycodone OR pentazocine OR methadone OR codeine OR dihydrocodeine OR dextromoramide OR diamorphine OR dextropropoxyphene OR meptazinol OR sufentanil OR alfentanil OR remifentanil OR nalbuphine OR dipipanone OR pethidine OR tramadol OR buprenorphine OR supportive pain medication OR tricyclic antidepressant OR amitriptyline OR desipramine OR doxepine OR clomipramine OR levomepromazine OR haloperidol OR carbamazepine OR gabapentin) [Words] </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2012-07-03 09:30:52 +0100" MODIFIED_BY="Angela Gunn" NO="6">
<TITLE MODIFIED="2012-07-03 09:30:52 +0100" MODIFIED_BY="Angela Gunn">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-05-18 16:47:25 +0100" MODIFIED_BY="Angela Gunn">
<P>#1MeSH descriptor Motor Neuron Disease explode all trees<BR/>#2"motor neuron disease" OR "motor neurone disease" OR "motoneuron disease" OR "motorneuron disease" OR "amyotrophic lateral sclerosis"<BR/>#3(Gehrig* NEAR syndrome*)<BR/>#4(Gehrig* NEAR disease*)<BR/>#5(#1 OR #2 OR #3 OR #4)<BR/>#6pain NEAR/3 relie* or pain NEAR/3 treatment or analgesic* or nonsteroidal or antiinflammatory agent or nsaid<BR/>#7aspirin or salicylates or indomethacin or piroxicam or ketorolac<BR/>#8tenoxicam or apazone or diclofenac or diflusinal or etodolac or fenoprofen or flurbiprofen or ibuprofen or ketoprofen or meclofenamate or nabumetone or naproxen or oxaprozin or phenylbutazone or sulindac or tolmetin or paracetamol or acetaminophen or APAP<BR/>#9MeSH descriptor Narcotics explode all trees<BR/>#10narcotic* or opioid* or opiate* or codeine<BR/>#11dihydrocodeine or dextromoramide or diamorphine or dextropropoxyphene or meptazinol or sufentanil or alfentanil or remifentanil or nalbuphine or dipipanone or pethidine or tramadol or buprenorphine<BR/>#12MeSH descriptor Analgesics explode all trees<BR/>#13analgesics or "supportive pain medication"<BR/>#14antidepressive NEAR/3 tricyclic<BR/>#15amitriptyline or desipramine or doxepine or clomipramine or levomepromazine or haloperidol or carbamazepine or gabapentin<BR/>#16anesthesia NEAR/2<BR/>adjuvant<BR/>#17MeSH descriptor Adjuvants, Anesthesia explode all trees<BR/>#18MeSH descriptor Anti-Inflammatory Agents, Non-Steroidal explode all trees<BR/>#19MeSH descriptor Pain, this term only with qualifiers: DT,PC,TH<BR/>#20(#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19)<BR/>#21(#5 AND #20)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2013-04-30 09:55:01 +0100" MODIFIED_BY="Ruth Brassington" NO="7">
<TITLE MODIFIED="2013-04-30 09:54:58 +0100" MODIFIED_BY="Ruth Brassington">ClinicalTrials.gov and WHO ICTRP</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-30 09:55:01 +0100" MODIFIED_BY="Ruth Brassington">
<P>amyotrophic lateral sclerosis AND pain</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>